Updated Friday, December 15, 2017
 Journal Tools
RSS Feed
Sample Copy
Submit a Manuscript
Contact Us
Subscription
Advertising
Thanking Peer Reviewers
 Language Polishing
Journal of Integrative Medicine: Volume 12, 2014   Issue 4,  Pages: 346-358

DOI: 10.1016/S2095-4964(14)60034-0
Systematic Review
Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis
1. Zhong-liang Liu (Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China )
2. Wei-rong Zhu (Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China )
3. Wen-chao Zhou (Department of Science and Technology, Putuo District Central Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China )
4. Hai-feng Ying (Department of Traditional Chinese Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 210000, China )
5. Lan Zheng (Department of Traditional Chinese Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 210000, China )
6. Yuan-biao Guo (Department of Traditional Chinese Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 210000, China )
7. Jing-xian Chen (Department of Traditional Chinese Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 210000, China )
8. Xiao-heng Shen (Department of Traditional Chinese Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 210000, China )

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted treatment has been a standard therapy for advanced non-small cell lung cancer (NSCLC), but it is not tolerated well by all patients. In China, some studies have reported that traditional Chinese medicinal herbs (TCMHs) may increase efficacy and reduce toxicity when combined with EGFR-TKI, but outside of China few studies of this kind have been attempted.

OBJECTIVE: This study is intended to systematically review the existing clinical evidence on TCMHs combined with EGFR-TKI for treatment of advanced NSCLC.

SEARCH STRATEGY: PubMed, the Cochrane Library, the Excerpta Medica Database (EMBASE), the China BioMedical Literature (CBM), and the China National Knowledge Infrastructure (CNKI) and web site of the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the World Conference of Lung Cancer (WCLC) were searched; the search included all documents published in English or Chinese before October 2013.

INCLUSION CRITERIA: We selected randomized controlled trials based on specific criteria, the most important of which was that a TCMH plus EGFR-TKI treatment group was compared with an EGFR-TKI control group in patients with advanced NSCLC.

DATA EXTRACTION AND ANALYSIS: The modified Jadad scale was used to assess the quality of studies. For each included study, patient characteristics, treatment details, therapeutic approach and clinical outcomes were collected on a standardized form. When disagreements on study inclusion or data extracted from a study emerged, the consensus of all coauthors provided the resolution. The clinical outcome metrics consisted of objective response rate (ORR; complete response + partial response divided by the total number of patients), disease control rate (DCR; complete response + partial response + no change divided by the total number of patients), survival rate, improved or stabilized Karnofsky performance status (KPS), and severe toxicity. RevMan 5.0 software was used for data syntheses and analyses. Risk ratio (RR) and 95% confidence interval (CI) were calculated; if the hypothesis of homogeneity was not rejected (P>0.1, I2<50%), the fixed-effect model was used to calculate the summary RR and the 95% CI. Otherwise, a random-effect model was used.

RESULTS: In this review, 19 studies were included based on the selection criteria. Of them, 13 studies were of high quality and 6 studies were of low quality, according to the modified Jadad scale. When the TCMH plus EGFR-TKI treatment groups were compared with the EGFR-TKI control groups the meta-analysis demonstrated a statistically significant higher ORR (RR 1.34; 95% CI 1.15 to 1.57; P=0.000 2), DCR (RR 1.18; 95% CI 1.09 to 1.27; P<0.000 1), one-year survival rate (RR 1.21; 95% CI 1.01 to 1.44; P=0.04), 2-year survival rate (RR 1.91; 95% CI 1.26 to 2.89; P=0.002) and improved or stable KPS (RR 1.38; 95% CI 1.26 to 1.51; P<0.000 01). Severe toxicity for rash was decreased (RR 0.55; 95% CI 0.32 to 0.94; P=0.03), as were nausea and vomiting (RR 0.17; 95% CI 0.04 to 0.72; P=0.02) and diarrhea (RR 0.46; 95% CI 0.24 to 0.89; P=0.02). Sensitivity analysis indicated that findings of the meta-analysis were robust to study quality. In the funnel plot analysis, asymmetry was observed, and publication bias was indicated by Egger’s test (P=0.03).

CONCLUSION: TCMH intervention can increase efficacy and reduce toxicity when combined with EGFR-TKI for advanced NSCLC, although this result requires further verification by more well designed studies.

Welcome to JIM! You are the number 8729 reader of this article!
Download Article:
[Full Text]      [PDF]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Liu ZL, Zhu WR, Zhou WC, Ying HF, Zheng L, Guo YB, Chen JX, Shen XH. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis. J Integr Med. 2014; 12(4): 346-358.
References:
1Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship[J].Mayo Clin Proc, 2008, 83(5): 584-594.  
2Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med, 2009, 361(10): 947-957.  
3Lee JS, Park K, Kim SW. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for neversmokers with advanced or metastatic adenocarcinoma of the lung[M]. San Francisco: 13th World Conference on Lung Cancer, 2009. abstract PRS.4.  
4Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study[J].Clin Cancer Res, 2006, 12(20 Pt 1): 6049-6055.  
5Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, J?nne PA. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer[J].J Clin Oncol, 2007, 25(7): 760-766.  
6Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 1[J].J Clin Oncol, 2004, 22(5): 777-784.  
7Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 2[J].J Clin Oncol, 2004, 22(5): 785-794.  
8Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J].J Clin Oncol, 2005, 23(25): 5892-5899.  
9Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial[J].J Clin Oncol, 2007, 25(12): 1545-1552.  
10Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban Gonzalez E, Molinier O, Klingelschmitt G, Giaccone G, on behalf of the SATURN Investigators. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with first-line platinum-based chemotherapy in patients with advanced NSCLC[J].J Clin Oncol, 2009, 27(15S): abstract 8001.  
11Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203)[J].J Clin Oncol, 2010, 28(5): 753-760.  
12Douillard JY, Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu YL, Li LY, Sellers M, Lowe E. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02[J].J Thorac Oncol, 2007, 2(8): S305-S306.  
13Vamvakas L, Agelaki S, Kentepozidis NK, Karampeazis A, Pallis AG, Christophyllakis C, Kotsakis AP, Boukovinas I, Mavroudis D, Georgoulias V. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial[J].J Clin Oncol, 2010, 28(15S): abstract 7519.  
14K?hler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review[J].Onkologie, 2013, 36(9): 510-518.  
15Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na?ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)[J].Ann Oncol, 2013, 24(1): 54-59.  
16Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial[J].Cancer, 2012, 118(24): 6234-6242.  
17Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study[J].Cancer, 2013, 119(15): 2754-2764.  
18Tang JL, Peng JY, Lu ZB. Clinical observation on Yanshu injection for rash caused by tyrosine kinase inhibitor[J].Zhongguo Zhong Yi Yao Zi Xun, 2011, 3(23): 378.  
19Chen X, Liu L, Zhou H, Yang XB, Chen SL, Tian XY, Wu WY. Comparison analysis of differentially expressed plasma proteins in patients with advanced non-small cell lung cancer treated with Kangai Fuzheng decoction and gefitinib[J].Xian Dai Zhong Xi Yi Jie He Za Zhi, 2013, 22(14): 1487-1490.  
20Jia YJ, Li XJ, Zhang Y, Sun YY, Chen L, Chen LW. Combination of Kanglaite Injection and tarceva in the treatment of non-small cell lung cancer[J].Guang Ming Zhong Yi, 2010, 25(2): 235-236.  
21Lü L, Miao JH, Chen SB, Zhang JW. Clinical study of gefitinib combined with Aidi Injection in treatment of non-small-cell lung cancer[J].Qiqihaer Yi Xue Yuan Xue Bao, 2006, 27(17): 2057-2059.  
22Deng J. Cinobufotalin combined with gefitinib in the treatment of advanced non-small-cell lung cancer: a clinical observation[J].Zhongguo Xian Dai Yao Wu Ying Yong, 2007, 1(11): 29-30.  
23The Nordic Cochrane Centre, the Cochrane Collaboration. Review Manager (RevMan) (Computer program). Version 5.0. [2010-10-22]. http://tech.cochrane.org/revman/download.
24World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization. 1979.
25Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status[J].Cancer, 1980, 45(8): 2220-2224.  
26DerSimonian R, Laird N. Meta-analysis in clinical trials[J].Control Clin Trials, 1986, 7(3): 177-188.  
27Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. West Sussex: John Wiley & Sons. 2000.
28McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials[J].J Clin Oncol, 2006, 24(3): 419-430.  
29Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials[J].Dement Geriatr Cogn Disord, 2001, 12(3): 232-236.  
30Breierova L, Choudhari M. An introduction to sensitivity analysis[M]. Massachusetts: Massachusetts Institute of Technology, 1996. 41-107.  
31Egger M, Davey SG, Altman DG. Systematic reviews in health care: meta-analysis in context. London: BMJ Books. 2001.
32Liu H, Hou W, Wang H, Lin HS. Clinical research on Shenyi Capsule combined with gefitinib for advanced non-small cell lung cancer: a report of 50 cases[J].Zhong Yi Za Zhi, 2012, 53(11): 933-935, 966.  
33Fu DZ. Clinical observation of Renshen Erling Decoction integrated with erlotinib in the treatment of advanced non-small cell lung cancer[J].Zhonghua Zhong Yi Yao Xue Kan, 2013, 31(2): 442-443.  
34Shi QH, Chen GF. Clinical observation of Kanglaite Injection combined with gefitinib in the treatment of non-small cell lung cancer with EGFR positive in medium or late stage[J].An Mo Yu Kang Fu Yi Xue, 2013, 4(4): 76-77.  
35Zhou J, Jiang YL. Clinical research of Yifei Decoction integrated with gefitinib for advanced non-small cell lung cancer: a report of 30 cases[M]. Beijing: National Academic Conference of Traditional Chinese Medicine for Tumor, 2011. 101-103.  
36Zhang Q, Yuan H. Clinical observation of Kanglaite Injection combined with gefitinib in the treatment of advanced non-small cell lung cancer: a report of 78 cases[J].Zhong Liu, 2011, 31(1): 89-90.  
37Zhang JL, Liu DY, Chen J. Clinical observation of Aidi Injection combined with gefitinib for advanced non-small cell lung cancer[J].Zhongguo Mei Rong Yi Xue, 2011, 20(5): 37.  
38Fang F, Chen H, Xiao Y, Duan AH, Du GP, Bu CF. Clinical evaluation of gefitinib combined with Zhenqi Fuzheng capsule in treatment of senile advanced non-small-cell lung cancer[J].Zhonghua Lao Nian Yi Xue Za Zhi, 2012, 31(1): 33-35.  
39Fang F, Chen H, Zhao H, Pan T, Yang H, Dai SM. Clinical observation of gefitinib combined with Pingxiao capsule in treatment of advanced NSCLC[J].Zhongguo Xian Dai Yi Xue Za Zhi, 2011, 21(7): 883-886.  
40Fang F, Chen H, Pang HM, Song WG, Wang RL, Wang HB. Clinical observation of gefitinib combined with Zilongjin tablets in treatment of advanced non-small-cell lung cancer[J].Xian Dai Yu Fang Yi Xue, 2011, 38(7): 1346-1348.  
41Fang H. Clinical observation of gefitinib combined with Aidi Injection in the treatment of advanced non-small cell lung cancer[J].Jian Kang Bi Du Za Zhi, 2011, (8): 28-29.  
42Yang XX, Shi HB, Hu WW, Wu J. Effects of Huisheng Oral Liquid combined with gefitinib on coagulation function and quality of life in patients with advanced non-small cell lung cancer[J].Lin Chuang Hui Cui, 2012, 27(23): 2093-2096.  
43Liang H, Wang YQ, Li YM, Zhou Q, Zhang H. Clinical study on 30 cases of advanced lung adenocarcinoma treated with TCM treatment based on syndrome differentiation combined with gefitinib[J].Guo Ji Zhong Yi Zhong Yao Za Zhi, 2012, 34(6): 502-505.  
44Yuan GR, Pan ZM. Clinical research of Sha Shen Mai Dong Tang on alleviating toxic and side reaction of Iressa[J].Zhonghua Zhong Yi Yao Xue Kan, 2011, 29(4): 930-932.  
45Jia YJ, Huang MN, Sun YY, Chen J, Li XJ, Chen L. Clinical study of Tarceva in combination with Xiaoyantang plus-minus prescriptions in treatment of non-small cell lung cancer[J].Lin Chuang Zhong Liu Xue Za Zhi, 2009, 14(7): 622-624.  
46Guo J, Wang N. Clinical observation of Kanglaite Injection combined with erlotinib in the treatment of advanced non-small cell lung cancer[J].Hebei Yi Yao, 2013, 35(5): 685-686.  
47Qian J, Qin SK, Yang LQ, Chen YX, Shao ZJ. The clinical study of gefitnib combination with Kanglaite Injection in treatment of non-small cell lung cancer[J].Lin Chuang Zhong Liu Xue Za Zhi, 2004, 9(6): 568-570.  
48Huang Y, Liu FL. Clinical study of Bufeidingchuan Prescription combined with gefitinib in treatment of advanced lung cancer[J].Zhongguo Yi Yao Zhi Nan, 2011, 9(35): 23-24.  
49Lin YT. Clinical research on treating NSCLC in TCM plus molecular targeted medicine[J].Zhong Yi Lin Chuang Yan Jiu, 2013, 5(10): 94-95.  
50Hu ZJ, Zhang SS, Xu XY. Clinical observation of erlotinib combined with Ankangxin capsule in the treatment of advanced non-small cell lung cancer: a report of 80 cases[J].Guangxi Yi Ke Da Xue Xue Bao, 2013, 30(2): 263-264.  
51Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. West Sussex: John Wiley & Sons, Ltd. 2009.
52Han SY, Li PP. The study on the effect of Xiaoaiping injection in reversing drug resistance to gefitinib of non-small cell lung cancer with K-ras mutations[M]. Ningbo: Proceedings of the 3rd International Academic Conference of Traditional Chinese Medicine and Integrative Medicine on Oncology and the 12th National Academic Conference of Integrative Medicine on Oncology, 2010. 475-481.  
 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号